Over 150 000 and 72 000 new cases of bladder cancer (BC) are estimated to be diagnosed each year in Europe and the United States, respectively ([@bib13]). When initially diagnosed, most are non-muscle invasive (NMIBC); that is, either non-invasive and confined to the mucosa (Ta and carcinoma *in situ* (CIS)) or invading the lamina propria (LP) but not yet the detrusor muscle (T1).

T1 of high cellular grade (HGT1), the subset of NMIBC with the highest risk of progression, may exhibit histopathological, clinical, and biological characteristics of invasive tumours. Even though classically 30% of these tumours have been considered to progress ([@bib28]), updated data show a 21% progression rate ([@bib29]). Therefore, a notable proportion of HGT1 behave in a relatively indolent manner and up to one-third resolve *ad integrum* after standard treatment ([@bib23]; [@bib16]). This wide range of tumour biology highlights the need to risk stratify these patients. Unfortunately, for high-risk NMIBC, both EORTC and CUETO scoring systems have poor discriminating ability and limited predictive value, tending to overestimate progression ([@bib29]; [@bib34]).

As a result, there is a need to reexamine management of HGT1 BC. Standard initial treatment is based on endoscopic transurethral resection (TUR), and intravesical immunotherapy with BCG. A repeat resection (reTUR) is recommended by guidelines to rule out understaging ([@bib1]; [@bib3]), even though for an array of reasons, reTUR remains underutilised with no higher than 7.7% of HGT1 patients reportedly undergoing this second procedure even at tertiary care centres ([@bib27]). ReTUR may improve outcome ([@bib15]) but adds morbidity and is probably unnecessary in over 60% of cases, while 6.5--30% might still progress ([@bib11]; [@bib26]). Conversely, prolongation of conservative treatment and deferring radical cystectomy may allow progression and decrease cancer-specific survival (CSS) ([@bib24], [@bib11]). Deciding upon ideal timing for cystectomy is one of the most difficult clinical decisions in urology and an ongoing area of controversy. This major surgical procedure requires urinary diversion, is associated with substantial morbidity (50-- 67% complication rate) and up to 9% mortality ([@bib2]), and may represent overtreatment ([@bib23]). Therefore, identifying those cases of HGT1 suitable for organ preservation and differentiating them from those that will most benefit from a timely cystectomy is a major challenge and key to improving outcomes.

Our group has been working to improve treatment strategy in HGT1 BC and, with others, has shown that substaging HGT1 according to the depth of LP invasion allows identification of patients at low (T1a) and high (T1b) risk of progression ([@bib21]; [@bib25]). Based on this evidence and to optimise resources, we designed a strategy by which a second TUR was indicated only in patients with deep LP invasion (T1b). In addition, because BCG response is also a strong predictor of progression, the second TUR was performed after a course of BCG induction. In the preliminary report of this series ([@bib20]), we showed that tumour size \>3 cm and associated CIS predict positive findings in the first evaluation at 3 months and speculated that HGT1a cases can safely forgo a second TUR.

In this study, we present the mature results of the first 200 cases of initial HGT1 treated with this optimised approach, at 71 months median follow-up, assessing recurrence, progression, and CSS, as well as evaluating clinical and histological features as prognostic factors.

Materials and methods
=====================

Trial design and inclusion of this prospective observational cohort study began in April 2005. Since then, patients diagnosed at initial TUR with HGT1 BC were offered entry into this protocol. Transurethral resection BT included complete resection of all visible tumours, with a separate base biopsy. Cold cup biopsies to detect CIS were taken, depending on surgeon preference, in a standardised manner or according to EAU Guidelines (abnormal urothelium, non-papillary tumour appearance, or positive cytology) ([@bib3]). All patients received a postoperative dose of intravesical mitomycin-C.

Tumours were graded according to the 2004 WHO system (2006) after pathological assessment of the total specimen. A two-tier system ([@bib8]) was used to assess the depth of LP invasion: T1a when tumour involved the subepithelial connective tissue superficial to muscularis mucosae (MM); T1b when tumour was found at the level of or beyond MM. When MM was not identifiable, thick-walled blood vessels deep in LP served as a landmark, or alternatively location of MM in tumour-free tissue of the same TUR was used for reference. Only initial HGT1 tumours with a visible, clearly identifiable and disease-free muscularis propria were included in this study. Patients with LP invasion (T1) but without muscularis propria in the specimen represent ∼10% of all T1 in our centre. These cases, identified as Tx, did not fulfill the requirements to enter this protocol and, following guidelines, directly underwent a repeat resection.

This protocol was approved by the Hospital Ethics Committee and registered at clinicaltrials.gov (NCT02113501), and last evaluation of patients was performed in February 2014. Enrolled subjects received six weekly instillations of 2--8 × 10^8^ UFC BCG-Tice (OncoTICE, Schering-Plough Canada Inc., Kirkland, QC, Canada) and, at 3 months after initial TUR, underwent either a second TUR post-BCG (T1b) or a cystoscopy plus cytology (T1a). Follow-up included BCG maintenance; the strategy is summarised in [Figure 1](#fig1){ref-type="fig"} and described in detail in our previous report ([@bib20]). Baseline characteristics were compared between the T1a and T1b groups using Fisher\'s exact test.

The primary objective was the assessment of progression, recurrence, and CSS. Progression was defined as occurrence of an invasive tumour at post-BCG TUR, the development of muscle invasive or more advanced stage carcinoma, distant metastasis, or death from BC. Time to progression was defined as time from diagnosis of BC to the date when disease progression was observed, or censored on the last known date alive without progression. Recurrence was defined as the first evidence of any NMIBC detected on follow-up. Time to recurrence was defined as time from diagnosis of BC to the date when disease recurrence was observed, or censored at the last known date alive without disease recurrence, or at date of progression. Cancer-specific survival was defined as death from the same cancer or related causes.

The secondary objective was the assessment of prognostic factors. Eleven clinical and pathological variables were prospectively documented to evaluate their capacity to predict events. Kaplan--Meier analysis was used to summarise median time to recurrence and time to progression. Association of time to recurrence, time to progression, and CSS with the variables of interest was assessed using Cox regression models in univariate and multivariable models, reporting hazard ratios (HRs) and 95% CI.

Results
=======

Two hundred primary urothelial HGT1 cases have been identified at TUR and have entered the present protocol. Median age at diagnosis was 71 years; 89.5% were males, with 89 (44.5%) cases being T1a and 111 (55.5%) T1b. Patients and tumour characteristics are shown in [Table 1](#tbl1){ref-type="table"} classified by substaging. The median follow-up period was 71 months (range: 5--107 months). The second TUR (performed only in T1b) was negative in 67.5% of cases and positive in the remaining 32.4% (11 invasive and 25 non-invasive; primary histology being persistent HGT1). Tolerance and patient dropout of BCG was not documented specifically within the study group, but for the broader population of high-risk BC at our hospital ∼30% do not complete the first year.

Recurrence was observed in 57 (28.5%) patients and disease progression in 31 (15.5%). In total, 46 patients died (13 of BC, 14 of other cancers, 18 of other causes, and one of unknown cause) and 18 underwent cystectomy (2 pT0, 1 pT1, 4 pTIS, 3 pT2, 4 pT3, and 3 pT4; one cystectomy at another centre; and 3 presented with positive lymph nodes). Ten potential candidates for cystectomy received palliative treatment because they were considered ineligible due to high surgical and/or anaesthetic risk.

The association of relevant clinical and pathological variables with time to progression and recurrence is presented in [Table 2](#tbl2){ref-type="table"}. Median time to recurrence was not reached; 2- and 5-year recurrence-free rates are summarised. Recurrence rate was not significantly different among HGT1a (21 cases, 22%) and HGT1b (36 cases, 34.6%), with only age at diagnosis remaining significant on multivariate analysis. [Table 3a and b](#tbl3a){ref-type="table"} summarise univariate and multivariate analysis for recurrence.

Progression rate demonstrated a significant difference based on substaging, with HGT1b tumours showing an increased risk of progression (5 T1a (5.6%) *vs* 26 T1b (23.6%)). Median time to progression was not reached; the 2- and 5-year progression-free rates are summarised in [Table 4a](#tbl4a){ref-type="table"}. Variables significant in univariate analysis together with lymphovascular invasion (LVI) and gender (significant in previous publications, but not in the current univariate analysis) were evaluated in a multivariable model for time to progression ([Table 4b](#tbl4b){ref-type="table"}). Substaging, CIS, and tumour size remained significant in this model. [Figure 2](#fig2){ref-type="fig"} illustrates the Kaplan--Meier curves for progression in relation to substaging, tumour pattern, tumour size, and associated CIS.[](#tbl4c){ref-type="table"}

The low number of deaths due to BC precluded analysis of predictors of CSS. Five-year CSS was 99% for T1a and 95% for T1b. Of the 13 patients who died due to BC (3 of local progression (no cystectomy) and 10 from metastatic BC, 6 of which had undergone cystectomy) all except one were originally T1b.

Finally, the association of TIS and tumour size in deeply invasive cases (T1b) gave an HR for progression of 4.81 with 95% CI (2.07, 11.20) (*P*=0.0003) for patients with T1b+CIS+\>3 cm compared with the rest.

Discussion
==========

In HGT1 BC, the proposed strategy of deferring a second TUR until after induction of BCG and doing so only in T1b cases, results in a global low progression rate of 15.5%. Cases in which tumours invaded the MM (T1b) had a three-fold increased risk of progression compared with those without MM invasion (T1a), even though the latter group was treated more conservatively. Our report goes on to confirm the role of CIS, tumour size, and tumour pattern as prognostic factors for worse outcomes in this group of high-risk non-muscle invasive BC.

To the best of our knowledge, this is the first report addressing the role of substaging HGT1 BC prospectively to guide therapeutic management. This novel strategy, together with the relatively large number of cases of initial HGT1, the long follow-up and the consistent treatment approach are the main strengths of our series. In addition, the evaluation of depth of tumour invasion was performed prospectively after TUR as part of the routine pathological report, whereas most reports on HGT1 are retrospective and observational. We cannot rule out bias due to patient selection since cases with recurrent tumours and those with no muscularis propria identified were not included; our series might also include some G2 cases (WHO 1974 classification) under the broader definition of HG BC. On the other hand, tumours that could have been understaged (early progressors or positive second TUR) were not excluded from the analysis in the understanding that this represents a more generalisable real-world practice, but might also be seen as a bias. Finally, our results are limited by the fact that the study was performed in a non-randomised manner. This limitation is widespread in the high-risk BC literature as most reports have retrospective observational designs, with few randomised studies ([@bib18]). Given the public nature of our health-care system, we chose to differentially allocate patients to treatment, using a more aggressive approach for T1b tumours, aiming to optimise resources.

The role of substaging has been well established throughout the past 20 years, with over 2500 published cases substaged according to invasion of the MM ([@bib25]). The relevance of this factor has been recently confirmed in the largest meta-analysis ever conducted on prognostic factors in HGT1 ([@bib18]). Because the evaluation of the depth of invasion is subject to interobserver and intraobserver variability, this parameter has been criticised for the last two decades, but there is growing evidence on the reproducibility of this evaluation. In a study specifically addressing this issue, [@bib8] elegantly showed a high concordance rate among general pathologists after guidance based only in a presentation of the staging systems as described by the SIGN guideline. In their report, the median K concordance rate was 0.623, which is higher than that attained for Gleason score among pathologists ([@bib5]). In a more recent report, [@bib25] showed a reclassification rate for substaging of only 16% after central review of 587 HGT1 BC tumour sets from a multicentre data set. Other methods to substage HGT1 have been described using either millimetric evaluation of the depth of invasion ([@bib7]; [@bib6]), measuring the size of the infiltrative tumour area as ⩽ or \> 1 high-power field ([@bib7]; [@bib4]) or describing the extent of invasion (microinvasive or extensive) ([@bib30]; [@bib32]). These alternative systems, however, have all been studied retrospectively in single data sets of patients and have not yet been externally validated ([@bib18]). A head-to-head comparison among these approaches in a large data set unfortunately is unavailable to date. Nonetheless, the fact that substaging remained a robust prognostic factor in our series (three-fold increase risk of progression in the adjusted multivariable model, and five-fold increase in the univariate model), even though patients with HGT1a underwent a more conservative approach demonstrates the magnitude of negative impact associated with depth of invasion.

We report a 15.5% progression rate, which is lower than the recently published pooled results of ∼20% progression rate for this high-risk group of tumours ([@bib29]; [@bib14]; [@bib18]). Progression rates for high-risk BC have typically been considered to be over 30% and up to 50%, but more current data support that approximately one in five cases progress and will typically do so within 48 months of initial diagnosis ([@bib29]). Our approach of proceeding with the second TUR after the 6-week induction of BCG ([@bib20]) was also used by [@bib9] with an overall progression rate of 41% in 132 patients. We contend that the better outcome in our series might be attributable to a complete, deep, and radical initial TUR together with the exclusion of cases without clear muscularis propria in the TURBT specimen. It is possible the use of BCG (induction and maintenance) and the second TUR have also contributed an added therapeutic benefit. The combined influence of all these factors might explain the low rate of understaging we found in the second TUR (9.9%) as well as the low rate of positive findings at 3 months ([@bib20]), but the limitations mentioned previously should also be taken into account. Mitomycin-C might have only played a minor role given that no impact on progression has been demonstrated with this agent in all randomised published trials. Also the proposed approach in delaying the second TUR makes it impossible to accurately differentiate between true understaging and early invasive recurrence.

Our study goes on to corroborate previous observations that CIS is a strong prognostic factor with a two-fold increase in risk of progression ([@bib28]). In our report, the impact was even stronger with a 0.23 HR favouring lack of CIS. Interestingly, we observed a high rate of detection in those patients who, according to surgeon preference, underwent multiple random bladder biopsies. This adds to the debate of whether routine bladder biopsies, which we have previously defended ([@bib20]), should be standardised at the time of initial BC TUR ([@bib19]). The usefulness of random bladder biopsies in the broad population of NMIBC is controversial ([@bib17]), but our findings suggest that a high positive yield is obtained in HGT1 cases. Alternatively, the diagnosis of CIS is based on its detection in either peritumoral areas of the specimen or if suspicious areas are biopsied. This approach, currently recommended by guidelines ([@bib1]; [@bib3]), is highly limited by interpretation and likely leads to underdetection of true CIS, even though fluorescence-guided TURBT might improve identification of suspicious areas of CIS ([@bib33]). Finally, the findings of our study suggest that larger tumours and those with a solid pattern are associated with a worse outcome in HGT1, are consistent with the relevance of these parameters in the broader NMIBC population. Combining these factors we observed that patients with T1b tumours that were larger than 3 cm and associated with CIS were 4.8 times more likely to progress than the rest.

We failed to demonstrate a worse prognosis for LVI and for females in any of the outcomes. The incidence of LVI was very low (under 5%) and, because its effects have been noted to correlate with depth of LP invasion, it is unclear whether LVI independently predicts outcome, or whether its detrimental impact is already captured by pathologic information on substaging ([@bib18]). Regarding gender, large population-based studies may be required to confirm a worse prognosis of females that has been suggested previously ([@bib22]).

In summary, our report proposes a novel approach for HGT1 BC based on the selection of patients who will most benefit from a second TUR, specifically those with deep invasion of the MM (T1b). The main clinical implication of separately identifying almost half of HGT1 cases with T1a substaging as having a low (4%) progression rate is that they can be spared a second endoscopic procedure with no harm. More accurate risk stratification incorporating depth of invasion, associated CIS, and tumour size would enable improved resource allocation for reTUR. It would also help identify optimal candidates for prompt cystectomy, namely T1b tumours larger than 3 cm and with associated CIS. If the one in five HGT1 patients who will eventually develop a muscle invasive BC could be identified after diagnostic TUR, then cystectomy could be offered more selectively. Also, overtreatment and the morbidity and anxiety of undergoing additional procedures could be spared in patients with more indolent prognosis. Our results further support the notion that the 'rule of thirds for HGT1\' (i.e., one-third will never recur, one-third will require deferred cystectomy, and one-third will die of disease) is currently outdated.

Given the low impact of available scoring systems and biological markers ([@bib32]), and in view of this data, depth of invasion might be considered as the strongest prognostic factor for progression in HGT1. In addition, recent evidence suggests that histopathological classification into pTa, pT1a, and pT1b can be translated into a molecular signature, reflecting progressive dysregulation to more invasive stages ([@bib10]). Based on the prognostic impact of T1 substaging in the present and previous studies, we believe there is an argument for evolution of the current TNM classification. Together with tumour size and the detection of CIS an updated classification would help to identify the patients most suitable for cystectomy. Randomised control trials to evaluate the positive impact of this subclassification of tumours would also be beneficial.

Conclusions
===========

With this contemporary approach for the management of HGT1 BC, in which the strategy of complete initial TUR+MitC+BCG is only followed by a second TUR in T1b cases, low recurrence and progression rates (28.5% and 15.5%, respectively) are achieved. Together with LP substaging (T1a *vs* T1b), tumour size and associated CIS are also prognostic factors for progression, which should be contemplated in future strategies and aid in the selection of patients for cystectomy.
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![**Summary of the protocol.** For all patients with positive findings at 3 months, the final decision about treatment, including the option of cystectomy, was taken according to disease status and the patient\'s preference. Fourteen percent cases did not receive immediate MitC post-TUR. BCG maintenance schedule consisted of three weekly instillations of Oncotice at 3 months and every 6 months thereafter (for 2--3 years depending on tolerance). \*According to physician advice and patients choice. Abbreviations: BRB=bladder random biopsies; TUR=trans urethral resection.](bjc2014633f1){#fig1}

![**(**A**) Association of *substaging* and time to progression.** (**B**) Association of *tumour pattern* and time to progression. (**C**) Association of *tumour size* and time to progression. (**D**) Association of *CIS* and time to progression.](bjc2014633f2){#fig2}

###### Association of clinical and histological variables with substaging (T1a *vs* T1b)

                                                       **T1a**   **T1b**   **Total**   ***P***
  ---------------------------------------------------- --------- --------- ----------- ------------
  Age (years) (\<70/⩾70)                               44/45     52/59     96/104      0.78
  Gender: Male/Female                                  79/10     100/11    179/21      0.82
  Tumour size: \<3 cm/\>3 cm                           55/34     59/52     114/86      0.14
  Tumour number: solitary/multiple                     49/40     60/51     109/91      \>0.99
  Tumour pattern: papillary/solid                      84/5      82/29     166/34      **0.0001**
  Lymphovascular invasion: yes/no                      1/88      6/105     7/193       0.09
  Micropapillary[a](#t1-fn3){ref-type="fn"}: yes/no    3/86      12/99     15/185      0.06
  Squamous metaplasia: yes/no                          21/68     40/71     61/139      0.06
  CIS[a](#t1-fn3){ref-type="fn"}: yes/no               17/72     40/71     57/143      **0.01**
  CIS in prostate[b](#t1-fn4){ref-type="fn"}: yes/no   0/79      7/93      7/172       **0.02**

Abbreviation: CIS=carcinoma *in situ*.

Subjects with T1b disease presented with significantly higher rates of solid pattern, associated bladder CIS and prostate CIS.

133 Patients underwent random bladder biopsies.

Only evaluated in male patients.

###### Univariate analysis for association of clinically and pathologically relevant variables with time to recurrence and time to progression

                                     **Recurrence**      **Progression**                        
  ---------------------------------- ------------------- ----------------- -------------------- --------------
  Age (years) \<70/⩾70               0.5 (0.29, 0.86)    **0.01**          0.59 (0.29, 1.22)    0.15
  Gender: Male/Female                0.81 (0.37, 1.78)   0.59              1.09 (0.33, 3.59)    0.89
  Tumour size: \<3 cm/\>3 cm         0.59 (0.35, 0.99)   **0.04**          0.44 (0.22, 0.91)    **0.02**
  Tumour number: solitary/multiple   0.68 (0.40, 1.14)   0.14              0.66 (0.33, 1.34)    0.25
  Tumour pattern: papillary/solid    0.76 (0.39, 1.47)   0.41              0.37 (0.17, 0.78)    **0.006**
  Lymphovascular invasion: yes/no    2.63 (0.95, 7.27)   0.06              3.11 (0.94, 10.28)   0.06
  Micropapillary\*: yes/no           0.69 (0.23, 2.21)   0.53              0.99 (0.24, 4.19)    0.99
  Squamous metaplasia: yes/no        1.18 (0.68, 2.04)   0.57              1.00 (0.46, 2.17)    0.99
  CIS: yes/no                        0.71 (0.41, 1.25)   0.23              0.23 (0.46, 2.17)    **\<0.0001**
  CIS in prostate: yes/no            0.84 (0.20, 3.44)   0.80              0.45 (0.11, 1.88)    0.26
  Substaging: T1a/T1b                0.61 (0.36, 1.04)   0.07              0.21 (0.08, 0.54)    **0.0004**

Abbreviations: CI=confidence interval; CIS=carcinoma *in situ*. \*Any % of micropapillary component. *P*\<0.05 represent statistically significant values (shown in bold).

###### Univariate analysis for recurrence; association of tumour size and age at diagnosis with time to recurrence at 2 and 5 years (only showing variables with significant *P*-values)

                ***N***   **Recur**   **Recurrence free at 2 years**   **Recurrence free at 5 years**   **Hazard ratio and 95% CI**   ***P***
  ------------- --------- ----------- -------------------------------- -------------------------------- ----------------------------- ----------
  Tumour size                                                                                                                         **0.04**
   \<3 cm       113       27          0.81 (0.72, 0.87)                0.76 (0.67, 0.83)                0.59 (0.35, 0.99)              
   \>3 cm       86        30          0.72 (0.60, 0.80)                0.59 (0.46, 0.70)                1 (reference)                  
  Age at dx                                                                                                                           **0.01**
   \<70         96        20          0.85 (0.76, 0.91)                0.78 (0.67, 0.85)                0.50 (0.29, 0.86)              
   ⩾70          103       37          0.70 (0.59, 0.78)                0.58 (0.47, 0.69)                1 (reference)                  

Abbreviation: CI=confidence interval. *P*\<0.05 represent statistically significant values (shown in bold).

###### Multivariable analysis for recurrence; association of CIS, substaging, tumour size, tumour pattern, lymphovascular invasion and gender with time to recurrence

                                  **Hazard ratio and 95% CI**   ***P***
  ------------------------------- ----------------------------- ----------
  Substaging (T1a)                0.64 (0.37, 1.14)             0.13
  CIS (No)                        0.68 (0.38, 1.21)             0.19
  Size (\<3 cm)                   0.59 (0.34, 1.01)             0.06
  Pattern (papillary)             1.12 (0.53, 2.37)             0.78
  Lymphovascular invasion (yes)   2.16 (0.71, 6.59)             0.18
  Gender (male)                   0.81 (0.36, 1.81)             0.60
  Age (\<70 years)                0.50 (0.29, 0.87)             **0.01**

Abbreviations: CI=confidence interval; CIS=carcinoma *in situ*. *P*\<0.05 represent statistically significant values (shown in bold).

###### Univariate analysis for progression; association of substaging, tumour pattern, size and whether patients had CIS with time to progression at 2 and 5 years (only showing variables with significant *P*-values)

                       ***N***   **Prog**   **Progression free at 2 years**   **Progression free at 5 years**   **Hazard ratio and 95% CI**   ***P***
  -------------------- --------- ---------- --------------------------------- --------------------------------- ----------------------------- --------------
  **Substaging**                                                                                                                              **0.0004**
   T1a                 89        5          0.95 (0.90, 0.99)                 0.80 (0.71, 0.86)                 0.21 (0.08, 0.54)              
   T1b                 110       26         0.81 (0.72, 0.87)                 0.74 (0.61, 0.83)                 1 (reference)                  
  **Tumour pattern**                                                                                                                          **0.006**
   Papillary           165       21         0.91 (0.85, 0.94)                 0.87 (0.80, 0.92)                 0.37 (0.17, 0.78)              
   Solid               34        10         0.73 (0.55, 0.85)                                                   1 (reference)                  
  **Tumour size**                                                                                                                             **0.04**
   \<3 cm              113       12         0.91 (0.84, 0.95)                 0.87 (0.75, 0.93)                 0.59 (0.35, 0.99)              
   \>3 cm              86        19         0.83 (0.73, 0.90)                 0.76 (0.64, 0.85)                 1 (reference)                  
  **CIS**                                                                                                                                     **\<0.0001**
   Yes                 56        18         0.71 (0.57, 0.81)                 0.60 (0.39, 0.76)                 1 (reference)                  
   No                  143       13         0.94 (0.89, 0.97)                 0.90 (0.83, 0.95)                 0.23 (0.11, 0.48)              

Abbreviations: CI=confidence interval; CIS=carcinoma *in situ*. *P*\<0.05 represent statistically significant values (shown in bold).

###### Multivariable analysis for progression; association of significant variables in univariate analysis together with lymphovascular invasion and gender were analysed

                                  **Hazard ratio and 95% CI**   ***P***
  ------------------------------- ----------------------------- ------------
  Substaging (T1a)                0.30 (0.12, 0.81)             **0.02**
  CIS (No)                        0.24 (0.12, 0.81)             **0.0002**
  Size (\<3 cm)                   0.41 (0.19, 0.87)             **0.02**
  Pattern (papillary)             0.68 (0.31, 1.48)             0.33
  Lymphovascular invasion (yes)   2.07 (0.60, 7.10)             0.25
  Gender (male)                   1.23 (0.37, 4.12)             0.74

Abbreviations: CI=confidence interval; CIS=carcinoma *in situ*. *P*\<0.05 represent statistically significant values (shown in bold).

###### Combined risk for the association of T1b, larger tumour size and associated CIS

                     **Hazard ratio and 95% CI**   ***P***
  ------------------ ----------------------------- ------------
  Substaging (T1a)   0.25 (0.12, 0.52)             **0.0002**
  CIS (no)           0.28 (0.11, 0.73)             **0.009**
  Size (\<3 cm)      0.40 (0.19, 0.84)             **0.014**

Abbreviations: CI=confidence interval; CIS=carcinoma *in situ*. *P*\<0.05 represent statistically significant values (shown in bold).
